Dimitrios Nasioudis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/603239/publications.pdf

Version: 2024-02-01

113	1,766	304368	377514
papers	citations	22 h-index	34 g-index

113	113	113	2447
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neutrophil gelatinase-associated lipocalin and innate immune responses to bacterial infections. Medical Microbiology and Immunology, 2015, 204, 471-479.	2.6	76
2	Primary lymphoma of the female genital tract: An analysis of 697 cases. Gynecologic Oncology, 2017, 145, 305-309.	0.6	67
3	Î±-Amylase in Vaginal Fluid: Association With Conditions Favorable to Dominance of Lactobacillus. Reproductive Sciences, 2015, 22, 1393-1398.	1.1	63
4	Cardiac Tumors in Pediatric Patients: A Systematic Review. World Journal for Pediatric & Congenital Heart Surgery, 2017, 8, 624-632.	0.3	58
5	Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2017, 4, ofw246.	0.4	58
6	Influence of Pregnancy History on the Vaginal Microbiome of Pregnant Women in their First Trimester. Scientific Reports, 2017, 7, 10201.	1.6	57
7	Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva Ginecologica, 2019, 71, 155-162.	0.8	55
8	Laparoscopic cholecystectomy during pregnancy: A systematic review of 590 patients. International Journal of Surgery, 2016, 27, 165-175.	1.1	52
9	Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases. Archives of Gynecology and Obstetrics, 2017, 296, 327-334.	0.8	50
10	Malignant urachal neoplasms: A population-based study and systematic review of literature. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 33.e11-33.e19.	0.8	46
11	Malignant Brenner tumors of the ovary; a population-based analysis. Gynecologic Oncology, 2016, 142, 44-49.	0.6	45
12	Urinary tract infections caused by <scp>ESBL</scp>â€producing Enterobacteriaceae in renal transplant recipients: A systematic review and metaâ€analysis. Transplant Infectious Disease, 2017, 19, e12759.	0.7	44
13	Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. Gynecologic Oncology, 2017, 144, 414-419.	0.6	38
14	Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. Journal of Gynecologic Oncology, 2017, 28, e46.	1.0	36
15	A population-based analysis of a rare oncologic entity: Malignant pancreatic tumors in children. Journal of Pediatric Surgery, 2018, 53, 647-652.	0.8	36
16	Mullerian dysgenesis: a critical review of the literature. Archives of Gynecology and Obstetrics, 2017, 295, 1369-1381.	0.8	34
17	Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clinical Genitourinary Cancer, 2019, 17, e447-e453.	0.9	34
18	Changes in the Vaginal Microbiome during the Pregnancy to Postpartum Transition. Reproductive Sciences, 2021, 28, 1996-2005.	1.1	33

#	Article	IF	Citations
19	Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecologic Oncology, 2017, 147, 296-301.	0.6	30
20	Extramammary Paget disease of the vulva: Management and prognosis. Gynecologic Oncology, 2020, 157, 146-150.	0.6	28
21	Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors. Gynecologic Oncology, 2017, 145, 243-247.	0.6	27
22	Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecologic Oncology, 2017, 147, 493-496.	0.6	27
23	Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?. Journal of Gynecologic Oncology, 2017, 28, e71.	1.0	27
24	Solid pseudopapillary and malignant pancreatic tumors in childhood: A systematic review and evidence quality assessment. Pediatric Blood and Cancer, 2018, 65, e27114.	0.8	24
25	Properties of Epithelial Cells and Vaginal Secretions in Pregnant Women When Lactobacillus crispatus or Lactobacillus iners Dominate the Vaginal Microbiome. Reproductive Sciences, 2018, 25, 854-860.	1.1	24
26	Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecologic Oncology, 2018, 150, 14-18.	0.6	24
27	Group B streptococcus alters properties of vaginal epithelial cells inÂpregnant women. American Journal of Obstetrics and Gynecology, 2016, 214, 383.e1-383.e5.	0.7	23
28	Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. American Journal of Obstetrics and Gynecology, 2021, 224, 195.e1-195.e17.	0.7	23
29	Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?. Gynecologic Oncology, 2017, 147, 81-84.	0.6	22
30	Safety of Fertility-Sparing Surgery for Premenopausal Women With Sex Cord-Stromal Tumors Confined to the Ovary. International Journal of Gynecological Cancer, 2017, 27, 1826-1832.	1.2	21
31	Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecologic Oncology, 2016, 141, 128-133.	0.6	20
32	Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecologic Oncology, 2019, 154, 302-307.	0.6	20
33	Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature. International Journal of Gynecological Cancer, 2020, 30, 1372-1377.	1.2	20
34	Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes. International Journal of Surgery, 2016, 35, 76-82.	1.1	19
35	Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis. International Journal of Gynecological Cancer, 2018, 28, 932-938.	1.2	18
36	Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors. Gynecologic Oncology Reports, 2019, 28, 145-148.	0.3	18

#	Article	IF	Citations
37	Trends in the surgical management of malignant ovarian germcell tumors. Gynecologic Oncology, 2020, 157, 89-93.	0.6	18
38	IL-1Î² predicts IVF outcome: a prospective study. Journal of Assisted Reproduction and Genetics, 2018, 35, 2031-2035.	1.2	17
39	The composition of the vaginal microbiome in first trimester pregnant women influences the level of autophagy and stress in vaginal epithelial cells. Journal of Reproductive Immunology, 2017, 123, 35-39.	0.8	16
40	Does tumor grade influence the rate of lymph node metastasis in apparent early stage ovarian cancer?. Archives of Gynecology and Obstetrics, 2018, 298, 179-182.	0.8	16
41	Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population. Maturitas, 2017, 96, 45-50.	1.0	15
42	Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. International Journal of Gynecological Cancer, 2020, 30, 1089-1094.	1.2	15
43	Primary Urinary Tract Lymphoma: Rare but Aggressive. Anticancer Research, 2017, 37, 6989-6995.	0.5	13
44	Ovarian preservation for low-grade endometrial stromal sarcoma: a systematic review of the literature and meta-analysis. International Journal of Gynecological Cancer, 2019, 29, 126-132.	1.2	13
45	Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer. Gynecologic Oncology, 2020, 159, 732-736.	0.6	13
46	Laparoendoscopic single-site surgery (LESS) for major urological procedures in the pediatric population: A systematic review. International Journal of Surgery, 2016, 29, 53-61.	1.1	12
47	Malignant Transformation of Vaginal Endometriosis - A Review of Literature. Gynecologic and Obstetric Investigation, 2017, 82, 105-112.	0.7	12
48	Role of early amniotomy with induced labor: a systematic review of literature and meta-analysis. American Journal of Obstetrics & Gynecology MFM, 2019, 1, 100052.	1.3	11
49	Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis. Gynecologic Oncology, 2020, 157, 634-638.	0.6	11
50	Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. Journal of Assisted Reproduction and Genetics, 2019, 36, 2485-2491.	1.2	10
51	Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?. Archives of Gynecology and Obstetrics, 2020, 301, 1047-1054.	0.8	10
52	Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors. International Journal of Gynecological Cancer, 2021, 31, 829-834.	1.2	10
53	Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 2, 100012.	0.6	9
54	Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors. Journal of Gynecologic Oncology, 2019, 30, e19.	1.0	9

#	Article	IF	Citations
55	Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature. Gynecologic Oncology, 2020, 158, 476-483.	0.6	9
56	Fertility preserving surgery for high-grade epithelial ovarian carcinoma confined to the ovary. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 248, 63-70.	0.5	9
57	Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size <2 cm: a systematic review and meta-analysis. International Journal of Gynecological Cancer, 2021, 31, 983-990.	1.2	9
58	Maternal and neonatal outcomes with mechanicalÂcervical dilation plus misoprostol comparedÂto misoprostol alone for cervical ripening; aÂsystematic review of literature andÂmetaanalysis. American Journal of Obstetrics & Gynecology MFM, 2019, 1, 101-111.	1.3	8
59	Isolated distant lymph node metastases in ovarian cancer. Should a new substage be created?. Gynecologic Oncology Reports, 2019, 28, 86-90.	0.3	8
60	Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base. Gynecologic Oncology, 2020, 156, 315-319.	0.6	8
61	Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy. Gynecologic Oncology, 2020, 157, 613-618.	0.6	8
62	The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 840-845.	1.2	8
63	Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database. Surgical Oncology, 2021, 38, 101589.	0.8	8
64	Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes. Anticancer Research, 2018, 38, 5811-5817.	0.5	7
65	Incidence of isolated para-aortic lymph node metastasis in early stage endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 242, 43-46.	0.5	7
66	Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors. International Journal of Gynecological Cancer, 2019, 29, 554-559.	1.2	7
67	Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer. Gynecologic Oncology, 2020, 159, 758-766.	0.6	7
68	Brain Metastases From Gynecologic Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 418-421.	0.6	7
69	Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes. Archives of Gynecology and Obstetrics, 2020, 302, 481-486.	0.8	7
70	Lymphadenectomy for early-stage mucinous ovarian carcinoma. International Journal of Gynecological Cancer, 2021, 31, 104-109.	1.2	7
71	Impact of surgical approach on prevalence of positive peritoneal cytology and lymph-vascular invasion in patients with early-stage endometrial carcinoma: a National Cancer Database study. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002445.	1.2	7
72	Outcomes of comprehensive lymphadenectomy for patients with advanced stage ovarian carcinoma and rare histologic sub-types. International Journal of Gynecological Cancer, 2021, 31, 1132-1136.	1.2	7

#	Article	IF	Citations
73	Epigenetics and the vaginal microbiome: influence of the microbiota on the histone deacetylase level in vaginal epithelial cells from pregnant women. Minerva Ginecologica, 2019, 71, 171-175.	0.8	7
74	Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix. International Journal of Gynecological Cancer, 2020, 30, 619-625.	1.2	6
75	Survival following minimally invasive radical hysterectomy for patients with cervical carcinoma and tumor size â‰¥2 cm. American Journal of Obstetrics and Gynecology, 2021, 224, 317-318.e2.	0.7	6
76	Is there a benefit of performing an omentectomy for clinical stage I high-grade endometrial carcinoma?. Surgical Oncology, 2021, 37, 101534.	0.8	6
77	Fertility-sparing surgery for patients with stage IC2 or IC3 epithelial ovarian carcinoma: any evidence of safety?. International Journal of Gynecological Cancer, 2022, 32, 165-171.	1.2	6
78	Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation. International Journal of Gynecological Cancer, 2022, 32, 823-827.	1.2	6
79	Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma. Gynecologic Oncology, 2019, 154, 401-404.	0.6	5
80	Surgical and oncologic outcomes of minimally invasive surgery for stage I high-grade endometrial cancer. Surgical Oncology, 2020, 34, 7-12.	0.8	5
81	Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma. Gynecologic Oncology, 2020, 157, 335-339.	0.6	5
82	Minimally invasive hysterectomy for stage IA cervical carcinoma: a survival analysis of the National Cancer Database. International Journal of Gynecological Cancer, 2021, 31, 1099-1103.	1.2	5
83	Risk of Second Primary Tumors After Childhood and Adolescent Ovarian Malignancies: A SEER Analysis (1973â€“2011). Journal of Pediatric and Adolescent Gynecology, 2015, 28, 522-525.	0.3	4
84	Minimally Invasive Staging of Apparent Stage I Malignant Ovarian Germ Cell Tumors: Prevalence and Outcomes. Journal of Minimally Invasive Gynecology, 2019, 26, 471-476.	0.3	4
85	Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 238, 86-89.	0.5	4
86	Disparities in the Use of Adjuvant External Beam Radiation Therapy in Node-positive Cervical Cancer Patients Following Hysterectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 43-46.	0.6	4
87	Primary malignant ovarian carcinoid; management and outcomes. Gynecologic Oncology, 2020, 157, 101-105.	0.6	4
88	High serum IGF-1 levels are associated with pregnancy loss following frozen-thawed euploid embryo transfer cycles. Journal of Reproductive Immunology, 2018, 127, 7-10.	0.8	3
89	Acute Myeloid Leukemia Following Gynecologic Cancer in the Era of Platinum-Based Chemotherapy. International Journal of Gynecological Cancer, 2018, 28, 1639-1642.	1.2	3
90	Increased Risk of Breast and Uterine Cancer Among Women With Ovarian Granulosa Cell Tumors. Anticancer Research, 2019, 39, 4971-4975.	0.5	3

#	Article	IF	Citations
91	Utilization and outcomes of sentinel lymph node biopsy in patients with early stage vulvar cancer. International Journal of Gynecological Cancer, 2021, 31, 40-44.	1.2	3
92	Surveillance Only for High-risk FIGO Stage IA/IB Malignant Ovarian Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 195-199.	0.6	3
93	Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1579-1583.	1.2	3
94	Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 2021, 31, 480-483.	1.2	2
95	Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion. International Journal of Gynecological Cancer, 2022, 32, 1129-1134.	1.2	2
96	Role of adjuvant chemotherapy for patients with FIGO stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion. Gynecologic Oncology, 2021, 162, S267-S268.	0.6	1
97	Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma. Gynecologic Oncology, 2021, 162, S270.	0.6	1
98	78: Group B streptococcus alters properties of vaginal epithelial cells in pregnant women to promote its persistence. American Journal of Obstetrics and Gynecology, 2016, 214, S56-S57.	0.7	0
99	Reply to â€œIs there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?â€• by Iavazzo et al. Archives of Gynecology and Obstetrics, 2021, 303, 599-600.	0.8	0
100	Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma. Gynecologic Oncology, 2021, 161, 705-709.	0.6	0
101	Multimodality adjuvant treatment is associated with a survival benefit for patients with stage IIIC uterine carcinosarcoma. Gynecologic Oncology, 2021, 162, S209.	0.6	0
102	Impact of delay in adjuvant chemotherapy administration for patients with advanced-stage epithelial ovarian carcinoma undergoing primary debulking surgery with bowel resection. Gynecologic Oncology, 2021, 162, S176.	0.6	0
103	Addition of external beam radiation therapy to adjuvant chemotherapy is associated with a survival benefit for patients with stage IIIC endometrioid carcinoma. Gynecologic Oncology, 2021, 162, S81.	0.6	0
104	Emergency department utilization by gynecologic cancer patients during the COVID-19 pandemic: unintended improvements in the selective use of emergency care?. Gynecologic Oncology, 2021, 162, S147.	0.6	0
105	Quality and outcomes of hysterectomy performed at low-income hospitals for patients with apparent early-stage endometrial cancer. Gynecologic Oncology, 2021, 162, S248-S249.	0.6	0
106	Adjuvant treatment for patients with stage IIIB endometrioid endometrial cancer following hysterectomy. Gynecologic Oncology, 2021, 162, S83-S84.	0.6	0
107	Impact of facility volume on the outcomes of minimally invasive radical hysterectomy for early-stage cervical cancer. Gynecologic Oncology, 2021, 162, S178.	0.6	0
108	Outcomes of ovarian preservation for women aged â‰¤50 years with stage I adenosarcoma undergoing hysterectomy. Gynecologic Oncology, 2021, 162, S223.	0.6	0

#	Article	IF	Citations
109	Impact of surgical para-aortic lymph node staging for patients with advanced-stage cervical carcinoma undergoing definitive chemoradiation. Gynecologic Oncology, 2021, 162, S184.	0.6	0
110	Ascites volume at the time of primary debulking and overall survival of patients with advanced-stage epithelial ovarian cancer. Gynecologic Oncology, 2021, 162, S91.	0.6	0
111	Underutilization of multigene panels among Ashkenazi Jewish patients.. Journal of Clinical Oncology, 2017, 35, 1533-1533.	0.8	0
112	Patterns of genetic screening for hereditary cancer syndromes: Effect of Supreme Courtâ€™s ruling invalidating single gene patent rights.. Journal of Clinical Oncology, 2017, 35, 1580-1580.	0.8	0
113	Early mortality in epithelial ovarian cancer.. Journal of Clinical Oncology, 2022, 40, e17585-e17585.	0.8	0